8-K: Verastem Advances Oncology Pipeline, Reports Strong Q3

Verastem, Inc. announced significant progress in its oncology pipeline, including the commercial launch of AVMAPKI FAKZYNJA CO-PACK and promising clinical data for VS-7375, alongside robust Q3 2025 net product revenue of $11.2 million.

Summary

• Verastem, Inc. filed an 8-K to provide its updated corporate presentation dated January 8, 2026, highlighting recent achievements and future priorities.
• The company achieved FDA approval for AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) for KRAS mutant-type recurrent Low-Grade Serous Ovarian Cancer (LGSOC) on May 8, 2025, two months ahead of its PDUFA action date.
• AVMAPKI FAKZYNJA CO-PACK was included in NCCN Guidelines as Category 2A for KRAS mt recurrent LGSOC.
• Net Product Revenue for Q3 2025 reached $11.2 million, following $2.1 million in Q2 2025, demonstrating strong commercial launch momentum with 133 prescribers.
• The Phase 3 RAMP 301 confirmatory trial for recurrent LGSOC (KRAS mt and wt) has completed IDMC recommended enrollment, with topline primary endpoint data expected by mid-2027.
• VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, showed positive early safety observations from its Phase 1/2a trial and received FDA Fast Track Designation (FTD) in Pancreatic Ductal Adenocarcinoma (PDAC).
• GenFleet Therapeutics, Verastem's partner in China, reported 68.8% Overall Response Rate (ORR) (N=16) for GFH375 (VS-7375) in 2L+ NSCLC and 58.3% ORR (N=12) in 2L PDAC.
• The RAMP 205 trial in 1L metastatic PDAC reported an 83% (10/12) confirmed ORR in Dose Level 1 with tumor shrinkage observed in all patients, and manageable adverse events.
• Verastem strengthened its financials through an Oberland debt refinancing and a November 2025 equity investment, extending its cash runway into the first half of 2027.
• The LGSOC commercial and development program is expected to be self-sustaining in the second half of 2026.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook, driven by a recent FDA approval ahead of schedule, strong initial commercial revenue, promising clinical data across its pipeline, and a significantly extended cash runway. The company is actively pursuing label expansion and advancing a potential best-in-class asset, addressing high unmet medical needs. While inherent risks in drug development remain, the current trajectory and financial position are strong.

Positives

• FDA approval for AVMAPKI FAKZYNJA CO-PACK was granted on May 8, 2025, two months ahead of the PDUFA action date of June 30, 2025.
• Strong commercial launch momentum for AVMAPKI FAKZYNJA CO-PACK, achieving $11.2 million in Net Product Revenue in Q3 2025, a significant increase from $2.1 million in Q2 2025.
• AVMAPKI FAKZYNJA CO-PACK received NCCN Guidelines inclusion as Category 2A for KRAS mt recurrent LGSOC, enhancing its market acceptance.
• The RAMP 301 confirmatory Phase 3 trial for recurrent LGSOC has completed IDMC recommended enrollment, progressing towards potential label expansion for both KRAS mutant and wild-type patients.
• VS-7375, a KRAS G12D (ON/OFF) inhibitor, demonstrated promising early safety and anti-tumor activity in its Phase 1/2a trial, clearing high dose levels (900 mg QD) with no dose-limiting toxicities (DLTs).
• VS-7375 received FDA Fast Track Designation (FTD) in PDAC, potentially accelerating its development and regulatory review.
• Preclinical data for VS-7375 shows better efficacy and durability compared to other G12D ON and Pan-RAS ON inhibitors, and it selectively spares T cell proliferation.
• The RAMP 205 trial in 1L metastatic PDAC reported an encouraging 83% confirmed Overall Response Rate (ORR) in the efficacy-evaluable population (10/12 patients) with manageable adverse events.
• The company's cash runway has been extended into the first half of 2027 due to Oberland debt refinancing and a $97.3 million follow-on equity offering in November 2025.
• The LGSOC commercial and development program is projected to become self-sustaining in the second half of 2026.

Negatives

• None explicitly mentioned regarding past performance or current results.

Risks

• Assumptions underlying forward-looking statements may prove incorrect.
• Risks related to the development and successful commercialization of product candidates, including obtaining and maintaining regulatory approvals, potential delays or rejections, and challenges with new product commercialization.
• History of operating losses and the possibility of never achieving or maintaining profitability.
• Inability to raise sufficient capital to fund ongoing operations or obtain financing on acceptable terms.
• Market demand for and acceptance of AVMAPKI FAKZYNJA CO-PACK may not meet expectations.
• Actions or advice of regulatory agencies could affect regulatory approval or maintenance of AVMAPKI FAKZYNJA CO-PACK.
• Impact of current and future healthcare reforms on the delivery of or payment for healthcare products and services.
• Uncertainties related to the activities and initiatives of the U.S. presidential administration, including regulatory and policy changes.
• Inability to obtain, maintain, and enforce patent and other intellectual property protection for product candidates.
• Decisions by regulatory authorities regarding trial design, labeling, and other matters could affect timing, availability, or commercial potential.
• Preclinical testing and preliminary/interim clinical data may not be predictive of results or success in ongoing or later clinical trials.
• Uncertainty regarding the timing, scope, and rate of reimbursement for product candidates by third-party payors.
• Market opportunities for drug candidates may be smaller than currently estimated.
• Competitive developments may result in others developing or commercializing products before or more successfully.
• Enrollment of clinical trials may take longer than expected, or data may not be available when expected.
• Failure to satisfy post-marketing requirements and commitments established with the FDA.
• Marketed product candidates may cause adverse safety events or unexpected concerns, leading to unmanageable safety profiles.
• Inability to confirm results from the RAMP 201 study or expand the approved indication for AVMAPKI FAKZYNJA CO-PACK.
• Manufacturing or supply interruptions or failures for product candidates.
• Reliance on third-party contract research organizations, manufacturing organizations, clinical sites, or contractors who may fail to fully perform.
• Failure of Verastem or partners (Pfizer, Chugai, GenFleet, Secura Bio) to fully perform under license or collaboration agreements.
• Inability to establish new or expand existing collaborations or partnerships on favorable terms.
• Potential material impact to the FDA's ability to engage in regulatory and oversight activities due to workforce reductions or budget changes.

Future Outlook

Verastem's 2026 priorities include maximizing the commercial launch of AVMAPKI FAKZYNJA CO-PACK, continuing the RAMP 301 confirmatory Phase 3 trial, maintaining a strong balance sheet, and generating monotherapy and combination data for VS-7375 to inform its registration path in major KRAS G12D solid tumors. The company plans to engage with the FDA in 1H 2026 to discuss development paths for PDAC, NSCLC, and CRC, including potential registration-directed trials. Key milestones for VS-7375 include interim monotherapy updates in 1H 2026, completing monotherapy expansion enrollment in 2H 2026, and initiating combination expansion cohorts for CRC, PDAC, and NSCLC in 2026. Topline data from RAMP 301 is expected by mid-2027, which could lead to U.S. label expansion and potential approvals in Japan and Europe by 2028-2029. The LGSOC program is expected to be self-sustaining by 2H 2026, and the company aims to initiate randomized registration-directed studies for VS-7375 in 2H 2026 into 2027, pursuing regulatory approvals from 2027 onwards.

Management Comments

• The company is focused on expeditiously developing and delivering transformative therapies that truly change outcomes for people living with RAS/MAPK pathway-driven cancers.
• Verastem is well-positioned to deliver continued commercial success and a potential best-in-class treatment for long-term growth, leveraging its clinical-to-commercial success and innovative pipeline.
• The company's scientific strategy is to target RAS directly, target the pathway downstream, and target the parallel pathway that drives resistance, offering a more complete blockade of signaling.

Industry Context

Verastem operates in the high-need oncology sector, specifically targeting RAS/MAPK pathway-driven cancers, which are notoriously challenging to treat. The approval of AVMAPKI FAKZYNJA CO-PACK addresses a significant unmet need in recurrent Low-Grade Serous Ovarian Cancer (LGSOC), a rare and aggressive cancer affecting younger women with limited effective treatment options. The development of VS-7375, a KRAS G12D (ON/OFF) inhibitor, positions Verastem in a highly competitive and rapidly evolving space for KRAS-mutated cancers, which are prevalent in PDAC, NSCLC, and CRC. The company's strategy of dual inhibition (RAF/MEK clamp + FAK inhibitor) and targeting both ON/OFF states of KRAS G12D aims to overcome resistance mechanisms and improve efficacy compared to existing or developing therapies, aligning with the industry trend towards precision oncology and combination therapies.

Comparison to Industry Standards

• For recurrent LGSOC, AVMAPKI FAKZYNJA CO-PACK (avutometinib + defactinib) demonstrated an Overall Response Rate (ORR) of 31% across all patients in RAMP 201, with a 10% discontinuation rate due to adverse events (AEs). This compares favorably to other treatments:
• Binimetinib (MILO study) showed a 16% ORR by BICR and a 31% discontinuation rate due to AEs.
• Trametinib (GOG 281) showed a 26% ORR by investigator assessment and a 36% discontinuation rate due to AEs.
• Standard hormonal therapy and chemotherapy typically offer 6-13% ORR with 17-30% discontinuation rates due to AEs.
• VS-7375, a KRAS G12D (ON/OFF) inhibitor, exhibits a differentiated preclinical profile compared to other RAS inhibitors like Revolution Medicine's RMC-6236 and RMC-9805, showing better efficacy and durability in KRAS G12D mutant tumor models.
• VS-7375's dual potent inhibition of both ON and OFF states of KRAS G12D, high affinity, long residence time, and selective inhibition (sparing T cell proliferation) suggest a potential best-in-class profile compared to other RAS inhibitors that may only target the ON state or have broader, less selective activity.

Stakeholder Impact

• **Shareholders:** Potential for increased shareholder value through successful commercialization of AVMAPKI FAKZYNJA CO-PACK, positive clinical trial outcomes for VS-7375, and extended cash runway into 2027.
• **Patients:** Development and commercialization of novel therapies for RAS/MAPK pathway-driven cancers, particularly for LGSOC and KRAS G12D-mutated solid tumors, address significant unmet medical needs.
• **Healthcare Providers:** AVMAPKI FAKZYNJA CO-PACK provides a new, effective, and tolerable treatment option for recurrent KRAS-mutated LGSOC, with potential for broader indication expansion.
• **Employees:** The company's scalable organization and continued clinical and commercial success suggest stability and growth opportunities.
• **Creditors:** The Oberland Finance Credit Facility provides substantial capital, with clear milestones for additional tranches, indicating a structured approach to financing.

Next Steps

• Maximize commercial launch execution of AVMAPKI FAKZYNJA CO-PACK for broad healthcare professional adoption.
• Continue execution of the RAMP 301 confirmatory Phase 3 trial in recurrent LGSOC, with topline data expected by mid-2027.
• Maintain a strong balance sheet and manage financial resources effectively.
• Generate monotherapy and combination data with VS-7375 to inform its registration path in major KRAS G12D solid tumors.
• Engage with the FDA in 1H 2026 to discuss development paths for PDAC, NSCLC, and CRC, including potential registration-directed trials.
• Report an interim update on VS-7375 monotherapy in 1H 2026 and complete enrollment in monotherapy expansion cohorts in 2H 2026.
• Complete enrollment in VS-7375 combination dose-escalation cohorts by mid-2026.
• Select the Recommended Phase 2 Dose (RP2D) and initiate the CRC combination expansion cohort in 1H 2026.
• Select the RP2D and initiate the PDAC and NSCLC combination expansion cohorts in 2H 2026.
• Report an update on the safety and efficacy of the RAMP 205 expansion cohort in 1H 2026.
• Initiate single-agent and combination randomized registration-directed studies for VS-7375 in 2H 2026 into 2027.
• Pursue regulatory approvals for VS-7375 from 2027 onwards.
• Leverage RAMP 301 results for potential U.S. label expansion and EU/Japan approvals for AVMAPKI FAKZYNJA CO-PACK in recurrent LGSOC regardless of KRAS mutation status (expected 2028-2029).

Key Dates

Recommendation

The filing presents a compelling case for a 'strong buy' recommendation. Verastem has achieved a significant milestone with the FDA approval of AVMAPKI FAKZYNJA CO-PACK ahead of schedule, demonstrating regulatory execution and market readiness. The initial commercial launch has shown robust revenue growth in Q3 2025, indicating strong market acceptance. The pipeline, particularly VS-7375, shows promising preclinical and early clinical data, positioning it as a potential best-in-class asset in the high-value KRAS G12D space. Furthermore, the company has significantly strengthened its financial position, extending its cash runway into 2027, which de-risks operations through key data readouts. The clear path for label expansion and the expectation for the LGSOC program to become self-sustaining by 2H 2026 underscore a strong growth trajectory and sound financial management, making it an attractive investment for seasoned investors.

Keywords

Verastem, Oncology, RAS/MAPK Pathway, Low-Grade Serous Ovarian Cancer, LGSOC, KRAS Mutant, Avutometinib, Defactinib, AVMAPKI FAKZYNJA CO-PACK, VS-7375, KRAS G12D Inhibitor, Pancreatic Cancer, PDAC, Non-Small Cell Lung Cancer, NSCLC, Colorectal Cancer, CRC, Clinical Trials, FDA Approval, Biotechnology, Pharmaceuticals, Cancer Therapy